FOR IMMEDIATE RELEASE
Areterna LLC, a subsidiary of Synthgene Biotech renowned for providing top-tier raw materials and services catering to mRNA and oligonucleotide therapeutics, has signed a global distribution agreement with BIORON GmbH, a premium manufacturer and worldwide-acting distributor of molecular biological and diagnostic products. Through this distribution relationship, customers in Europe will have easier access to high quality and cost-effective raw materials, products and services for their mRNA and Oligo research and manufacturing.
This strategic partnership is poised to streamline access to high-quality, cost-effective raw materials, products, and services for mRNA and oligo research and manufacturing across Europe. Through this collaboration, customers within the region will benefit from enhanced accessibility to resources vital for advancing their mRNA and oligo-related endeavors.
Marking a pivotal milestone in Areterna’s mission to democratize mRNA vaccines and therapeutics, this distribution agreement underscores the company’s commitment to delivering GMP-grade raw materials at competitive prices. Simon Koerpert, Senior Director of Business Development EU at Areterna LLC, underscored the significance of this alliance, affirming, “Through our collaboration with BIORON, we anticipate broadening our reach within the EU market, with the ultimate aim of facilitating more affordable raw materials to support mRNA therapeutics development.”
“Through our collaboration with BIORON, we anticipate broadening our reach within the EU market, with the ultimate aim of facilitating more affordable raw materials to support mRNA therapeutics development.”
Simon Koerpert, Senior Director of Business Development EU at Areterna LLC
The CEO of BIORON GmbH, Andreas Schweizer, echoed sentiments of excitement regarding the partnership, emphasizing a shared belief in the immense potential of mRNA-based vaccines and therapeutics. “Our collaboration with Areterna and Synthgene,” the CEO remarked, “positions us to provide added value to our clientele, offering access to premium raw materials at reduced costs. We eagerly anticipate the multitude of opportunities this partnership will unlock.”
“Our collaboration with Areterna and Synthgene,” the CEO remarked, “positions us to provide added value to our clientele, offering access to premium raw materials at reduced costs. We eagerly anticipate the multitude of opportunities this partnership will unlock.”
Andreas Schweizer, CEO of BIORON GmbH
About Areterna LLC:
Areterna LLC was founded in 2023 as a wholly owned subsidiary of Synthgene Biotechnology Co., Ltd. to serve customers in the US and Europe. Synthgene provides materials and services to support mRNA and oligonucleotide manufacturing. Founded in 2018 by a group of passionate nucleic acid chemists, the goal of the company is to debottleneck the raw material supply and develop innovative solutions to support customers in the industry. The company has a robust quality system and ISO9001 certification to support cGMP manufacturing of mRNA raw materials that include NTPs, modified NTPs and cap analogs. For the GMP raw materials, Drug Master Files have been filed with FDA. In addition, Synthgene offers analytical development service and mRNA-related impurity standards and detection kits, LNP screening service, IVT process development and IVT kits for mRNA research. For solid-phase DNA and RNA synthesis, Synthgene offers high quality phosphonamidites to support cGMP oligo manufacturing. With over 200 scientists in R&D and AI-assisted discovery platform, Synthgene will continue to bring new products to the market.
About BIORON GmbH:
BIORON GmbH is a premium manufacturer and worldwide-acting distributor of molecular biological and diagnostic products with more than 20 years of experience and innovation. Its head office is located in South-West Germany. BIORON´s specialization lies in the provision of raw materials which are supplied mainly to manufacturers of diagnostic products such as real-time PCR kits. Expansion is currently taking place in the area of Human DNA production. The company is holding the ISO 13485: 2016 certificate (medical). Due to its international orientation and focus on individual customer needs, the BIORON Team has long-term clients in the US, Europe – first of all Germany – and many other countries around the globe.